Your Location:Home >Products >Pharmaceutical >Sarms Powder Muslce Building ACP-105 CAS NO.899821-23-9
Product Details
1. Product Name: ACP-105
2. CAS NO.: 899821-23-9
3. Purity: 99% min
4. Standard: USP
5. MF: C16H19ClN2O
6. Appearance: white or almost white crystalline powder
Product Details
ACP-105, a novel non-steroidal SARM. It is shown to be as potent and efficacious as testosterone in in vitro assays without interaction at other hormone receptors. Moreover, ACP-105 demonstrates potent anabolic effects on muscle and bone with minimal effect on prostrate in preclinical models. ACP-105 is often a non-steroidal and selective androgen receptor agonist. ACP-105 belongs to a class of molecules called selective androgen receptor modulators (SARMs). SARMs may advance the standard of answer to a variety of disorders including muscle-wasting conditions and osteoporosis, with fewer unwanted effects as compared with current treatments based on testosterone replacement.
Item |
Value |
CAS No. |
899821-23-9 |
Other Names |
ACP 105 |
MF |
C18H18N2O |
Place of Origin |
China |
|
Shaanxi |
Type |
Immune Function Agents |
Grade Standard |
Food Grade, Medicine Grade, Tech Grade |
Brand Name |
XAZB |
Model Number |
ACP 105 |
Purity |
99% |
Product Name |
ACP 105 |
Appearance |
White fine powder |
Assay |
99.0~101.0% |
MOQ |
5gram |
Package |
Aluminum Foil Bag |
Function |
bodybuliding |
Payment |
TT.Western Union |
Sample |
Availiable |
Price |
Negotiable. Depends on quantity |
Funcation
Anabolism - promotion and growth of lean muscle tissue and mass. This is extremely important for the individual suffering from a muscle wasting disease. It is the muscle wasting that at times can lead to the demise of the patient even before the disease itself.
1) Increases in strength - again, excellent for those suffering from muscle wasting diseases. Increased bone density and strength - highly beneficial to the osteoporosis patient. SARMS may prove to be one of if not the most effective osteoporosis treatments available, although official data is still inconclusive.
2) Fat Loss - medications with strong androgen binding affinity have been shown to promote lipolysis. How significant these six SARMS are in this regard is inconclusive.
3) Low to No Virilization - this is highly important to women. Many compounds (anabolicandrogenic steroids) while the same benefits of anabolic steroids can apply to women as they do men, there is often the issue of virilization.
4) Endurance & Conditioning - All of the pre-clinical SARMS should have a level of positive effect on muscular endurance as well as overall physical conditioning. The level of effectiveness in such regards is dependent on the SARM in question and data is still inconclusive to quantify the total effects.
5) Nutrient Efficiency - All of the pre-clinical SARMS should have a positive impact on nutrient efficiency to one degree or
another. This refers to the ability of the body to make better use of the nutrients it consumes.
Application
ACP-105 is a drug which acts as a potent, orally active growth hormonesecretagogue, mimicking the GH stimulating action of the endogenous hormone ghrelin. It has been demonstrated to increase the release of, and produces sustained increases in plasma levels of several hormones including growth hormone and IGF-1, but without affecting cortisol levels. It is currently under development as a potential treatment for reduced levels of these hormones, such as in growth hormone deficient children or elderly adults, and human studies have shown it to increase both muscle mass and bone mineral density, making it a promising therapy for the treatment of frailty in the elderly. It also alters metabolism of body fat and so may have application in the treatment of obesity.
CAS:70288-86-7
CAS:747-36-4
CAS:626-55-1